TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Culturally Adapted Manual Assisted Cognitive Behavioral Therapy for Prevention of Self Harm: A Randomized Control Trial
Brief Summary: Aim:

To adapt and develop a culturally appropriate psychological intervention and test its feasibility, and acceptability for the patients presenting to general hospital following self-harm in Karachi Pakistan.

Primary hypothesis:

Patients who receive cognitive behavioral therapy will show significant decrease in suicidal ideation as compared to patients with treatment as usual.

Design:

Randomized Control Trial

Setting:

Medical Departments of General Hospitals in Karachi.

Participants:

A total of 200 self harm patients will be randomized to psychological intervention and treatment as usual arm.

Intervention:

Culturally Adapted Cognitive Behavioral Therapy (CBT)

Outcome measure:

Beck Suicidal Ideation Scale


Options:
A: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
B: Arm Label: Peer Mentorship intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer mentorship | Arm Label: Enhanced Usual Care (EUC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Peer mentorship; Assigned to Arm(s): Peer Mentorship intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care (EUC)
C: Arm Label: Dialectical behavior therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Arm Label: alternative psychotherapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Intervention Type: BEHAVIORAL; Name: Dialectical behavior therapy (DBT); Assigned to Arm(s): Dialectical behavior therapy, alternative psychotherapy
D: Arm Label: MYPLAN app; Type: EXPERIMENTAL; Interventions: Other: MYPLAN-safety plan as an application for smart phones | Arm Label: Safety plan on paper; Type: ACTIVE_COMPARATOR; Interventions: Other: safety plan on paper | Intervention Type: OTHER; Name: MYPLAN-safety plan as an application for smart phones; Assigned to Arm(s): MYPLAN app | Intervention Type: OTHER; Name: safety plan on paper; Assigned to Arm(s): Safety plan on paper

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Culturally Adapted Manual Assisted Cognitive Behavioral Therapy for Prevention of Self Harm: A Randomized Control Trial
Brief Summary: Aim:

To adapt and develop a culturally appropriate psychological intervention and test its feasibility, and acceptability for the patients presenting to general hospital following self-harm in Karachi Pakistan.

Primary hypothesis:

Patients who receive cognitive behavioral therapy will show significant decrease in suicidal ideation as compared to patients with treatment as usual.

Design:

Randomized Control Trial

Setting:

Medical Departments of General Hospitals in Karachi.

Participants:

A total of 200 self harm patients will be randomized to psychological intervention and treatment as usual arm.

Intervention:

Culturally Adapted Cognitive Behavioral Therapy (CBT)

Outcome measure:

Beck Suicidal Ideation Scale


Options:
A: Arm Label: MYPLAN app; Type: EXPERIMENTAL; Interventions: Other: MYPLAN-safety plan as an application for smart phones | Arm Label: Safety plan on paper; Type: ACTIVE_COMPARATOR; Interventions: Other: safety plan on paper | Intervention Type: OTHER; Name: MYPLAN-safety plan as an application for smart phones; Assigned to Arm(s): MYPLAN app | Intervention Type: OTHER; Name: safety plan on paper; Assigned to Arm(s): Safety plan on paper
B: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
C: Arm Label: No text messages; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Supportive and interactive text messages; Type: EXPERIMENTAL; Interventions: Other: Supportive and interactive text messages | Intervention Type: OTHER; Name: Supportive and interactive text messages; Assigned to Arm(s): Supportive and interactive text messages
D: Arm Label: Attachment Based Family Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Attachment Based Family Therapy | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Attachment Based Family Therapy; Assigned to Arm(s): Attachment Based Family Therapy | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Culturally Adapted Manual Assisted Cognitive Behavioral Therapy for Prevention of Self Harm: A Randomized Control Trial
Brief Summary: Aim:

To adapt and develop a culturally appropriate psychological intervention and test its feasibility, and acceptability for the patients presenting to general hospital following self-harm in Karachi Pakistan.

Primary hypothesis:

Patients who receive cognitive behavioral therapy will show significant decrease in suicidal ideation as compared to patients with treatment as usual.

Design:

Randomized Control Trial

Setting:

Medical Departments of General Hospitals in Karachi.

Participants:

A total of 200 self harm patients will be randomized to psychological intervention and treatment as usual arm.

Intervention:

Culturally Adapted Cognitive Behavioral Therapy (CBT)

Outcome measure:

Beck Suicidal Ideation Scale


Options:
A: Arm Label: S-DBT; Type: EXPERIMENTAL; Interventions: Behavioral: Standard dialectical behavior therapy (SDBT) | Arm Label: DBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Individual DBT with no DBT group sessions (DBT-I) | Arm Label: DBT-S; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Skills DBT with no DBT individual sessions (DBT-S) | Intervention Type: BEHAVIORAL; Name: Standard dialectical behavior therapy (SDBT); Assigned to Arm(s): S-DBT | Intervention Type: BEHAVIORAL; Name: Individual DBT with no DBT group sessions (DBT-I); Assigned to Arm(s): DBT-I | Intervention Type: BEHAVIORAL; Name: Group Skills DBT with no DBT individual sessions (DBT-S); Assigned to Arm(s): DBT-S
B: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Other: Other | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Other; Assigned to Arm(s): Experimental Arm
C: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: venlafaxine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): N/A
D: Arm Label: Case management; Type: EXPERIMENTAL; Interventions: Behavioral: Case management | Arm Label: Enhanced usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Case management; Assigned to Arm(s): Case management | Intervention Type: OTHER; Name: Enhanced usual care; Assigned to Arm(s): Enhanced usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study Comparing a Patient-Centered Symptom Reporting Follow Up Program (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer
Brief Summary: This is a pilot study that will compare two systems of breast cancer follow up care and will evaluate a number of parameters indicating quality and efficiency of care delivery as well as patient satisfaction with care. Approximately 100 breast cancer patients who have completed the acute phase of treatment will be randomized to one of two follow up care plans.


Options:
A: Arm Label: intervention group; Type: ACTIVE_COMPARATOR; Interventions: Device: distress thermometer | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: distress thermometer; Assigned to Arm(s): intervention group
B: Arm Label: SIS.NET, Routine Follow up; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SIS.NET, Routine Follow-up | Intervention Type: BEHAVIORAL; Name: SIS.NET, Routine Follow-up; Assigned to Arm(s): SIS.NET, Routine Follow up
C: Arm Label: Standard Monitoring CEA/ Standard Imagery; Type: OTHER; Interventions: Procedure: Standard Monitoring CEA, Procedure: Standard Monitoring Imagery | Arm Label: Intensive monitoring CEA/ Standard Imagery; Type: OTHER; Interventions: Procedure: Intensive Monitoring CEA, Procedure: Standard Monitoring Imagery | Arm Label: Intensive Monitoring CEA / Intensive Monitoring Imagery; Type: OTHER; Interventions: Procedure: Intensive Monitoring CEA, Procedure: Intensive Monitoring Imagery | Arm Label: Standard Monitoring CEA/ Intensive Monitoring Imagery; Type: OTHER; Interventions: Procedure: Standard Monitoring CEA, Procedure: Intensive Monitoring Imagery | Intervention Type: PROCEDURE; Name: Standard Monitoring CEA; Assigned to Arm(s): Standard Monitoring CEA/ Intensive Monitoring Imagery, Standard Monitoring CEA/ Standard Imagery | Intervention Type: PROCEDURE; Name: Intensive Monitoring CEA; Assigned to Arm(s): Intensive Monitoring CEA / Intensive Monitoring Imagery, Intensive monitoring CEA/ Standard Imagery | Intervention Type: PROCEDURE; Name: Standard Monitoring Imagery; Assigned to Arm(s): Intensive monitoring CEA/ Standard Imagery, Standard Monitoring CEA/ Standard Imagery | Intervention Type: PROCEDURE; Name: Intensive Monitoring Imagery; Assigned to Arm(s): Intensive Monitoring CEA / Intensive Monitoring Imagery, Standard Monitoring CEA/ Intensive Monitoring Imagery
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: ca coli follow-up by GP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: ca coli follow-up by GP | Intervention Type: OTHER; Name: ca coli follow-up by GP; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study Comparing a Patient-Centered Symptom Reporting Follow Up Program (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer
Brief Summary: This is a pilot study that will compare two systems of breast cancer follow up care and will evaluate a number of parameters indicating quality and efficiency of care delivery as well as patient satisfaction with care. Approximately 100 breast cancer patients who have completed the acute phase of treatment will be randomized to one of two follow up care plans.


Options:
A: Arm Label: Postal Questionnaire; Type: EXPERIMENTAL; Interventions: Other: 15 Patient Reported Health Status Questions | Arm Label: Online Questionnaire; Type: EXPERIMENTAL; Interventions: Other: 15 Patient Reported Health Status Questions | Arm Label: Face-to-face Questionnaire; Type: EXPERIMENTAL; Interventions: Other: 15 Patient Reported Health Status Questions | Arm Label: Telephone Questionnaire; Type: EXPERIMENTAL; Interventions: Other: 15 Patient Reported Health Status Questions | Intervention Type: OTHER; Name: 15 Patient Reported Health Status Questions; Assigned to Arm(s): Face-to-face Questionnaire, Online Questionnaire, Postal Questionnaire, Telephone Questionnaire
B: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Behavioral: Baseline and Follow-up Surveys, Other: Patient Reported Outcome Measure informed Decision Aid | Arm Label: Non Treatment Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Baseline and Follow-up Surveys, Other: Pamphlet | Intervention Type: BEHAVIORAL; Name: Baseline and Follow-up Surveys; Assigned to Arm(s): Non Treatment Group, Treatment Group | Intervention Type: OTHER; Name: Patient Reported Outcome Measure informed Decision Aid; Assigned to Arm(s): Treatment Group | Intervention Type: OTHER; Name: Pamphlet; Assigned to Arm(s): Non Treatment Group
C: Arm Label: SIS.NET, Routine Follow up; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SIS.NET, Routine Follow-up | Intervention Type: BEHAVIORAL; Name: SIS.NET, Routine Follow-up; Assigned to Arm(s): SIS.NET, Routine Follow up
D: Arm Label: Intervention; Type: N/A; Interventions: N/A | Arm Label: Control; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dissemination of Tobacco Tactics Versus 1-800-QUIT-NOW for Hospitalized Smokers
Brief Summary: Nurse-administered smoking cessation interventions have been shown to be efficacious, but are seldom implemented due to lack of training and time. This project aims to disseminate and test the nurse-administered Tobacco Tactics intervention in 6 hospitals.


Options:
A: Arm Label: EMR reminder; Type: EXPERIMENTAL; Interventions: Other: EMR Reminder | Arm Label: EMR reminder + Panel management; Type: EXPERIMENTAL; Interventions: Other: EMR Reminder + Panel management | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EMR Reminder; Assigned to Arm(s): EMR reminder | Intervention Type: OTHER; Name: EMR Reminder + Panel management; Assigned to Arm(s): EMR reminder + Panel management
B: Arm Label: dosing decision support; Type: EXPERIMENTAL; Interventions: Other: weight based dosing decision support | Arm Label: no decision support; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: weight based dosing decision support; Assigned to Arm(s): dosing decision support
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention only; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention plus Direct-to-parent communication; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Intervention Type: BEHAVIORAL; Name: STAR - Study of Technology to Accelerate Research; Assigned to Arm(s): Clinician intervention only, Clinician intervention plus Direct-to-parent communication, Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dissemination of Tobacco Tactics Versus 1-800-QUIT-NOW for Hospitalized Smokers
Brief Summary: Nurse-administered smoking cessation interventions have been shown to be efficacious, but are seldom implemented due to lack of training and time. This project aims to disseminate and test the nurse-administered Tobacco Tactics intervention in 6 hospitals.


Options:
A: Arm Label: Osmotic-Release Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Osmotic-Release Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Osmotic-Release Methylphenidate; Assigned to Arm(s): Osmotic-Release Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: COPD cohort; Type: N/A; Interventions: N/A | Arm Label: Control cohort; Type: N/A; Interventions: N/A
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.


Options:
A: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
B: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)
C: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Brief Summary: The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
B: Arm Label: adalimumab + placebo; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo (vehicle ointment) | Arm Label: adalimumab + calcipotriol/betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: Calcipotriol/Betamethasone Ointment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone, adalimumab + placebo | Intervention Type: DRUG; Name: Calcipotriol/Betamethasone Ointment; Assigned to Arm(s): adalimumab + calcipotriol/betamethasone | Intervention Type: DRUG; Name: placebo (vehicle ointment); Assigned to Arm(s): adalimumab + placebo
C: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
D: Arm Label: Placebo/Adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Adalimumab | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo/Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Placebo/Adalimumab

Answer: C